Joseph G Rogers1, Andrew J Boyle2, John B O'Connell3, Douglas A Horstmanshof4, Donald C Haas5, Mark S Slaughter6, Soon J Park7, David J Farrar3, Randall C Starling8. 1. Division of Cardiology, Duke University, Durham, NC. Electronic address: joseph.rogers@duke.edu. 2. Cleveland Clinic Florida, Weston, FL. 3. Thoratec Corporation, Pleasanton, CA. 4. INTEGRIS Baptist Medical Center, Oklahoma City, OK. 5. Abington Memorial Hospital, Abington, PA. 6. University of Louisville, Louisville, KY. 7. University Hospitals Case Medical Center, Cleveland, OH. 8. Cleveland Clinic, Cleveland, OH.
Abstract
BACKGROUND: Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. OBJECTIVE: The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. METHODS: This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. CLINICAL CONTEXT: This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.
BACKGROUND: Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. OBJECTIVE: The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. METHODS: This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. CLINICAL CONTEXT: This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.
Authors: Samuel T Coffin; Dia R Waguespack; Nicholas A Haglund; Simon Maltais; Jamie P Dwyer; Mary E Keebler Journal: Cardiorenal Med Date: 2015-01-09 Impact factor: 2.041
Authors: Andreas P Kalogeropoulos; Raghda Al-Anbari; Ann Pekarek; Kristin Wittersheim; Maria A Pernetz; Amber Hampton; Jerilyn Steinberg; Vasiliki V Georgiopoulou; Javed Butler; J David Vega; Andrew L Smith Journal: Eur Heart J Cardiovasc Imaging Date: 2015-07-09 Impact factor: 6.875
Authors: Grace Cui; Walter J Akers; Michael J Scott; Michael Nassif; John S Allen; Anne H Schmieder; Krishna S Paranandi; Akinobu Itoh; Dmitry D Beyder; Samuel Achilefu; Gregory A Ewald; Gregory M Lanza Journal: Theranostics Date: 2018-02-02 Impact factor: 11.556
Authors: Jatin Anand; Steve K Singh; David G Antoun; William E Cohn; O H Bud Frazier; Hari R Mallidi Journal: Biomed Res Int Date: 2015-10-25 Impact factor: 3.411